ABSTRACT. We aimed to confirm the correlations between rs2359612 and rs9923231 single nucleotide polymorphisms (SNPs) in the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene and the risk of cardiovascular and cerebrovascular diseases (CCVDs) using metaanalysis. Electronic databases were exhaustively searched for relevant case-control studies by employing stringent inclusion and exclusion criteria. Manual retrieval was also conducted to obtain additional pertinent literature. The STATA statistical software was employed for the process of evidence synthesis. The initial literature search broadly identified 225 studies relevant to our topic of interest, and after multiple rounds of screening, 10 clinical case-control studies met the final inclusion criteria and were selected for this meta-analysis. The selected studies represented a combined total of 7329 patients with CCVD and 7951 healthy controls. Our meta-analysis demonstrated that the VKORC1 rs2359612 and rs9923231 SNPs were closely associated with high risk for CCVD (rs2359612: allelic: OR = 1.23, 95%CI = 1.00-1.50, P = 0.047; dominant: OR = 1.32, 95%CI = 1.19-1.46, P < 0.001; rs9923231: allelic: OR = 0.74, 95%CI = 0.63-0.87, P < 0.001; dominant: OR = 0.67, 95%CI = 0.55-0.82, P < 0.001). Our meta-analysis provides strong evidence that two SNPs in the VKORC1 gene, rs2359612 and rs9923231, contribute to the risk of CCVD.
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INTRODUCTION
Cardiovascular and cerebrovascular diseases (CCVD) together are major killers worldwide, and affect multiple organ systems causing dysfunction of the heart, brain, or blood vessels as a result of high blood pressure, atherosclerosis, heart enlargement, and easy blood clotting (Fuster and Bansilal, 2010; Tao et al., 2013) . CCVD is a collective term to include cardiovascular diseases (CVD) and cerebrovascular diseases (CBVD); furthermore, CVD itself has a wide disease range including coronary artery disease, peripheral vascular disease, dyslipidemias, heart failure, arrhythmia, and myocardial infarction as well as hypertension (Lee and Kim, 2014) . On the other hand, CBVD triggers neurological deficit, including brain disorders related to cerebral vascularization such as ischemic stroke, cerebrovascular anomalies, transient ischemic stroke, and hemorrhagic stroke (Patyar et al., 2011) . CCVD claims more than 17.3 million lives every year worldwide, and its incidence has seen a sharp 3-fold increase within the last decade in the United States (Fuster and Bansilal, 2010; Tao et al., 2013) . Multiple-recognized environmental factors including dyslipidemia, hypertension, diabetes mellitus, obesity, alcohol use, lack of physical activity, poor diet, tobacco use, and air pollution are linked to a high risk of CCVD (Kim and Johnston, 2011; Turin et al., 2012; Belanger et al., 2014) . In light of the high incidence and mortality of CCVD, we are interested in the underlying mechanisms with an aim of identifying causative factors; thus, we noted recent studies that suggested the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene as a leading candidate in the genetic predisposition to CCVD risk (Kim and Johnston, 2011; Owens, 2011; Holden et al., 2014) .
VKOR is a 163-amino acid polytopic membrane protein essential for the reductive branch of vitamin K required for modification of vitamin K-dependent protein in blood coagulation (Schulman et al., 2010; Tie et al., 2012) . Furthermore, VKOR is a multisubunit enzyme, and the single major peptide, VKORC1, is largely responsible for its reductase activity (Aomori et al., 2009) . VKORC1 is a polytopic membrane protein of the endoplasmic reticulum, and plays a prominent role in gamma-carboxylation of vitamin K-dependent coagulation factors and vitamin K-dependent matrix protein Gla, and reduces vitamin K to vitamin K hydroquinone (Wang et al., 2008; Tie et al., 2014) . Recently, an increasing number of studies have shown particular interest in two single nucleotide polymorphisms (SNPs) in the VKORC1 gene, rs2359612 and rs9923231, for their strong association with multiple-human disease conditions (Yang et al., 2010; Ragia et al., 2013) . These SNPs have since been found to be of great value in predicting the risk of CCVD (Ragia et al., 2013; Wang et al., 2013) . On the other hand, there are also studies reporting the lack of any correlation between VKORC1 SNPs and Genetics and Molecular Research 14 (4): 14731-14744 (2015) SNPs of VKORC1 and CCVD CCVD (Arnold et al., 2008; Lemmens et al., 2008) . Therefore, we performed the present metaanalysis with the purpose of evaluating whether VKORC1 SNPs can be risk factors in CCVD.
MATERIAL AND METHODS

Publication search
Electronic databases [PubMed, Embase, EBSCO, CINAHL, Web of Science, Springerlink, Cochrane Library, China BioMedicine (CBM), VIP, and China National Knowledge Infrastructure (CNKI)] since inception to October 2014 were searched, combined with a manual search using free words and key words. Our search terms included "VKORC1 protein, human" or "VKORC1" or "vitamin K epoxide reductase complex 1" or "vitamin K epoxide reductase" and "coronary disease" or "myocardial infarction" or "myocardial infarction" or "hypertension" or "arrhythmias, cardiac" or "blood pressure, high" or "CHD" or "arrhythmia" or "stroke" or "infarction" or "cerebral infarction" or "brain infarction" or "intracranial embolism" or "ischemic attack, transient" or "ITA".
Inclusion and exclusion criteria
The predefined inclusion criteria during the process of study selection in our metaanalysis were: 1) study design: clinical case-control studies regarding the correlation between SNPs of the VKORC1 gene and CCVD; 2) study subjects: patients with CCVD together with healthy controls; 3) detection methods: polymerase chain reaction-ligase detection reaction (PCR-LDR), PCR-restriction fragment length polymorphism (PCR-RFLP), TaqMan assay, and MassARRAY; and 4) outcome indicators: allele and dominant gene frequencies of patients and controls. The exclusion criteria were: 1) reviews, abstracts, letters, non-human studies, or duplicates; 2) studies unrelated to the research topic; 3) studies without complete data; and 4) non-Chinese or non-English publications.
Data extraction
Y. Li and J. Zhu independently undertook data extraction for meta-analysis based on a predefined form, and any disagreement was resolved after reaching a consensus among several investigators. The main information collected was as follows: first author, publication time, country, ethnicity, language, age, gender, study design, number of patients, detection method, disease, sample source, sample size, and SNP.
Statistical analysis
All statistical analyses of data were performed using the STATA version 12.0 software (Stata Corp., College Station, TX, USA). ORs with 95%CIs among study groups and Z-tests were employed to confirm the significance of the overall effect size (Chen et al., 2012) . The Cochran's Q-statistic (P < 0.05 was considered to be significant) and I 2 test (0%, no heterogeneity; 100%, maximal heterogeneity) were applied to reflect heterogeneity among studies (Peters et al., 2006; Jackson et al., 2012) . Additionally, the evidence of significant heterogeneity indicated the utilization of the random-effect model in the process of statistical analyses (P < Y. Li et al. 0.05 or I 2 test exhibited >50%), and if heterogeneity was absent, a fixed-effect model was employed (Higgins and Thompson, 2002; Zintzaras and Ioannidis, 2005b) . We utilized univariate meta-regression and multivariate-meta-regression analyses to evaluate possible sources of heterogeneity; in addition, multiple-calibration tests were conducted using the Monte Carlo method (Huizenga et al., 2011; Jackson et al., 2012) . Subsequently, sensitivity analyses were utilized to evaluate whether removal of each single study influenced the overall outcomes. Furthermore, the existence of publication bias was detected by funnel plot and contour-enhanced and Egger's linear regression tests (Zintzaras and Ioannidis, 2005a) . All tests were two-sided and P < 0.05 was considered to be significant.
RESULTS
Baseline characteristics of the studies included
A total of 225 published studies were initially retrieved by our search criteria and subsequently 215 studies were excluded for the following reasons: 55 studies for duplication; 12 for letters, reviews, and meta-analyses; 26 for non-human studies; 96 for no relation to the research topic; 8 for lack of data; and 18 for absence of relevant data. Finally, 10 clinical case-control studies (Watzka et al., 2007; Arnold et al., 2008; Lemmens et al., 2008; Shyu et al., 2010; Zhang and Zhang, 2012; Li, 2013; Ragia et al., 2013; Wang et al., 2006 Wang et al., , 2013 Niu and Wei, 2014) , published from 2006 to 2014 and representing 7329 patients with CCVD and 7951 healthy controls, were selected for this meta-analysis. Genotype distribution in the metaanalysis was consistent with Hardy-Weinberg equilibrium (HWE) (all P > 0.05). Six studies were performed in Asians and four in Caucasians. The present meta-analysis involves the SNPs of the VKORC1 gene, rs2359612, and rs9923231 (Figure 1 ). The SNP detection methods included PCR-LDR, PCR-RFLP, TaqMan, and MassARRAY. The baseline characteristics of the enrolled studies are listed in Table 1 . 
Correlation between rs2359612 and CCVD
Five of ten studies reporting the correlation between the rs2359612 SNP in the VKORC1 gene and CCVD showed significant heterogeneity (allelic: I 2 = 86.1%, P < 0.001; dominant: I 2 = 80.8%, P < 0.001), thus the random-effect model was used. Metaanalysis demonstrated a significant correlation between rs2359612 and the risk of CCVD (allelic: OR = 1.23, 95%CI = 1.00-1.50, P = 0.047; dominant: OR = 1.32, 95%CI = 1.19-1.46, P < 0.001) (Figure 2A and B) . A subgroup analysis based on ethnicity found that, in Asians, rs2359612 closely correlated with the risk of CCVD (allelic: OR = 1.54, 95%CI = 1.24-1.92, P < 0.001; dominant: OR = 1.63, 95%CI = 1.43-1.86, P < 0.001). However, in Caucasians, there was no notable correlation between rs2359612 and the risk of CCVD (allelic: OR = 1.01, 95%CI = 0.93-1.09, P = 0.879; dominant: OR = 1.01, 95%CI = 0.87-1.17, P = 0.918) ( Figure 3A and B and Table 2 ). Another subgroup analysis based on disease type suggested that, in the allelic model, there were no correlations between rs2359612 in patients with CVD and CBVD and the risk of CCVD (CVD: OR = 1.17, 95%CI = 0.99-1.39, P = 0.062; CBVD: OR = 1.28, 95%CI = 0.72-2.28, P = 0.409), while in the dominant model, rs2359612 in patients with CVD and CBVD notably correlated with the risk of CCVD (CVD: OR = 1.23, 95%CI = 1.07-1.40, P = 0.003; CBVD: OR = 1.43, 95%CI = 1.24-1.66, P < 0.001) ( Figure 3C and D) . 
Correlation between rs9923231 and CCVD
For rs9923231, five of ten studies reported correlations between this VKORC1 gene SNP and CCVD. rs9923231 showed absence of heterogeneity; therefore fixed-effect models were utilized (allelic: I 2 = 31.0%, P = 0.215; dominant: I 2 = 0.0%, P = 0.427). Meta-analysis results demonstrated that rs9923231 was strongly relevant to the risk of CCVD (allelic: OR = 0.74, 95%CI = 0.63-0.87, P < 0.001; dominant: OR = 0.67, 95%CI = 0.55-0.82, P < 0.001) ( Figure  2C and D and Table 2 ). Ethnicity subgroup analysis uncovered that, in Asians, rs9923231 was strongly relevant to the risk of CCVD (allelic: OR = 0.69, 95%CI = 0.57-0.83, P < 0.001; dominant: OR = 0.66, 95%CI = 0.53-0.83, P < 0.001). However, in Caucasians, there was no obvious correlation between rs9923231 and the risk of CCVD (allelic: OR = 0.92, 95%CI = 0.66-1.28, P = 0.617; dominant: OR = 0.73, 95%CI = 0.42-1.27, P = 0.263) ( Figure 3E and F). Another subgroup analysis on the basis of disease type showed that, in CVD, rs2359612 were significantly correlated with the risk of CCVD (allelic: OR = 0.68, 95%CI = 0.55-0.82, P < 0.001; dominant: OR = 0.64, 95%CI = 0.51-0.81, P < 0.001), while in CBVD, there was no obvious correlation between rs2359612 and the risk of CCVD (allelic: OR = 0.90, 95%CI = 0.67-1.19, P = 0.447; dominant: OR = 0.77, 95%CI = 0.51-1.17, P = 0.223) ( Figure 3G and H).
Sensitivity analysis and publication bias
Sensitivity analyses confirmed that no single study in our meta-analysis exerted significant influence on pooled ORs. For the correlation between the VKORC1 gene and the risk of CCVD, contour-enhanced funnel plots implied that the literature included were barely interspersed among P > 0.05, and further use of the Egger test demonstrated that publication bias was absent in the literature included (P > 0.05; Figure 4 ). 
Regression analysis
The results of univariate meta-regression analysis indicated that for rs2359612, detection methods, country, and ethnicity could represent possible sources for the heterogeneity in published reports regarding the correlation between the VKORC1 gene and patients with CCVD (detection methods: P = 0.003; country: P = 0.049; ethnicity: P = 0.007), while publication time and sample size were shown to be insignificant factors (all P > 0.05). For rs9923231, publication time, sample size, detection methods, country, and ethnicity were not related to the heterogeneity (all P > 0.05; Figure 5 ). Furthermore, multivariate meta-regression analysis results showed that publication time, sample size, detection methods, country, and ethnicity were not the main sources of heterogeneity (Tables 3 and 4 ). 
DISCUSSION
In this study, we investigated whether published studies could reveal a definitive link between two important SNPs in the VKORC1 gene and the risk of CCVD. The overall result in our meta-analysis is that rs2359612 and rs9923231 SNPs are associated with an increased risk of CCVD. VKORC1 regulates gamma-carboxylation of vitamin K-dependent proteins such as Gas6, matrix-GLA protein (MGP), osteocalcin, hemostatic proteins C, S, and Z, and coagulation factors II, VII, IX, and X (Smadja et al., 2008) . The rs2359612 and rs9923231 SNPs in the VKORC1 gene promote elevated expression of VKORC1, resulting in higher g-carboxylation of vitamin K-dependent proteins and vitamin K-dependent proteins involved in calcification, thus promoting vascular calcification through multiple mechanisms . Vascular calcification is an important marker that correlates with enhanced CCVD morbidity and mortality and MGP is an inhibitor of vascular calcification (Rennenberg et al., 2010b) . Rennenberg et al. (2010a) showed that more calcification is associated with higher serum undercarboxylated MGP levels. On the other hand, blood flow, coagulation factors, endothelial cells and platelets are components of the coagulation system and tissue factor is a potent initiator for coagulation cascade, which are associated with the pathophysiology of atherothrombosis and induceincluding platelet aggregation along with the activation of a coagulation cascade in patients with CCVD (Suh et al., 2009) . The fact that the coagulation factors II (prothrombin), VII, IX, and X, which have procoagulant activities, are regulated by VKORC1 suggests that SNPs that increase VKORC1 activity would have a strong impact on the coagulation pathway (Teichert et al., 2008) . Consistent with this, Pérez-Andreu et al. (2012) and Watzka et al. (2007) also concluded that VKORC1 is a relevant molecule that could be used to assess the risk of CCVD.
In order to assess other influencing factors affecting the validity of our overall results, our meta-analysis employed two subgroup analyses. The analysis based on ethnicity showed that significant correlations between the rs2359612 and rs9923231 SNPs and the risks of CCVD were found in an Asian population. To our surprise, given the importance of these two SNPs, no correlation of rs2359612 and rs9923231 with any significant risk of CCVD was identified in Caucasians. We suspect that genetic polymorphisms at other loci such as protein disulfide isomerase or in the loci for other members of the multi-subunit VKORC1 complex, geographical location of the study population, or limitations in existing detection methods could account for these observations, and we intend to follow up with further studies to address ethnic differences in the association of VKORC1 SNPs and CCVD risk. Another subgroup analysis based on disease type suggested the following results: in an allelic model, no correlations were found between rs2359612 SNPs in patients with CVD and CBVD and the risk of CCVD; in a dominant model, the rs2359612 SNP was significantly related to the risk of CCVD; and in patients with CVD, the rs2359612 SNP was significantly correlated with the risk of CCVD, whereas in CBVD, there was no obvious correlation between the rs2359612 SNP and the risk of CCVD.
As with all meta-analyses, some limitations to the interpretation of our data should be mentioned. First, diverse protein detection methods were used among the studies included, which might negatively influence our overall results. Second, the quantity of literature included was comparatively small, which might result in a lack of confidence in the pooled results. Finally, the inclusion and exclusion criteria might not be complete, which, together with manual selection, might lead to a reduction in the accuracy of the results by increasing the likelihood of having missed more detailed studies.
Collectively, our meta-analysis demonstrated that the rs2359612 and rs9923231 SNPs in the VKORC1 gene might contribute to the risk of CCVD. Considering the above-mentioned limitations, further detailed studies are warranted to understand the roles of VKORC1 SNPs in the risk of CCVD as a prelude to their clinical application.
